Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Ocrevus: A Rare First-Year Blockbuster

Executive Summary

Ocrevus generated roughly $935m in 2017 after launching in April, exceeding recent drug launches and putting the multiple sclerosis therapy in company with early successes like Opdivo, Ibrance, Tecfidera and Eylea.

Advertisement

Related Content

2018 Saw Record Launches, But No Big Splash
Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows
Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
All Systems Go as Roche MS Drug Ocrevus Secures EU Okay At Last
A Year To Remember For US Drug Launches
Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Head Of The Class: A Star Stands Out Among 2014 Drug Launches
Tecfidera Stands Out From The Pack Of 2013 Drug Launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel